Form 4: Tarsus Pharmaceuticals CFO Jeffrey Farrow Reports Stock Transactions

Jeffrey Farrow, CFO of Tarsus Pharmaceuticals, reports the acquisition and disposal of company stock related to the vesting and settlement of Restricted Stock Units (RSUs).

Summary

• On June 17, 2024, Jeffrey Farrow acquired 27,881 shares of Tarsus Pharmaceuticals common stock through the settlement of vested Restricted Stock Units (RSUs).
• Following this acquisition, Farrow disposed of 10,445 shares on June 18, 2024, at a price of $27.47 per share.
• The sale was to cover tax withholding obligations associated with the vesting of the RSUs and was mandated by the issuer.
• After these transactions, Farrow beneficially owns 18,136 shares of Tarsus Pharmaceuticals common stock.
• Farrow also holds 83,644 Restricted Stock Units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment about the company's performance or prospects. The transactions are related to compensation and tax obligations, which are normal business operations.

Positives

• The vesting of RSUs indicates that Farrow is meeting the conditions of his equity compensation plan.
• The sell-to-cover transaction ensures tax obligations are met without requiring Farrow to use personal funds.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors if they interpret it as a lack of confidence in the company's future performance.

Risks

• Executive stock sales, even for tax purposes, can sometimes create short-term price volatility.
• There is a risk of misinterpretation by investors regarding the reasons for the stock sale.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but it does outline the vesting schedule for the RSUs, indicating continued equity-based compensation for the reporting person.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects. Sell-to-cover transactions are standard practice to manage tax obligations related to equity compensation.

Comparison to Industry Standards

• Sell-to-cover transactions are a common practice among publicly traded companies to manage tax obligations related to equity compensation, aligning with industry standards.
• Equity compensation plans, such as the RSU grants to Jeffrey Farrow, are standard practice in the pharmaceutical industry to incentivize and retain key executives, similar to companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals.

Stakeholder Impact

• Shareholders may be interested in executive stock transactions as an indicator of management's confidence in the company.
• Employees may be interested in the details of the RSU plan as it relates to their own compensation.

Key Dates